Catalogue de tableaux modernes... Vente 24 janv. 1856... / [expert] Couteaux

[Vente. Estampes. 1856-01-24. Paris]

Iowa Crop and Weather Report, November 24, 2013 Vol 13, no.38

Report produced by the The Department of Agriculture and Land Stewardship, Climatology Bureau. Iowa Secretary of Agriculture Bill Northey today commented on the Iowa Crops and Weather report released by the USDA National Agricultural Statistical Service. The report is released weekly from April through October.

Fiscal Update, February 24, 2014

The Fiscal Division newsletter, published weekly during session and periodically during the interim.

EPI Update, January 24, 2014

Weekly newsletter for Center For Acute Disease Epidemiology of Iowa Department of Public Health.

Friday Facts, January 24, 2014, Vol. 200

Bureau of Nutrition and Health Promotion part of the Iowa Department of Public Health produces of weekly newsletter about the Iowa WIC Program for the State of Iowa citizen.

Combination of bevacizumab and 2-weekly pegylated liposomal doxorubicin as first-line therapy for locally recurrent or metastatic breast cancer. A multicenter, single-arm phase II trial (SAKK 24/06).

BACKGROUND: Pegylated liposomal doxorubicin (PLD) and bevacizumab are active agents in the treatment of metastatic breast cancer (MBC). We carried out a multicenter, single-arm phase II trial to evaluate the toxicity and efficacy of PLD and bevacizumab as first-line treatment in MBC patients. METHODS: Bevacizumab (10 mg/kg) and PLD (20 mg/m(2)) were infused on days 1 and 15 of a 4-week cycle for a maximum of six cycles. Thereafter, bevacizumab monotherapy was continued at the same dose until progression or toxicity. The primary objective was safety and tolerability, and the secondary objective was to evaluate efficacy of the combination. RESULTS: Thirty-nine of 43 patients were assessable for the primary end point. Eighteen of 39 patients (46%, 95% confidence interval 30% to 63%) had a grade 3 toxicity. Sixteen (41%) had grade 3 palmar-plantar erythrodysesthesia, one had grade 3 mucositis, and one severe cardiotoxicity. Secondary end point of overall response rate among 43 assessable patients was 21%. CONCLUSIONS: In this nonrandomized single-arm trial, the combination of bimonthly PLD and bevacizumab in locally recurrent and MBC patients demonstrated higher than anticipated toxicity while exhibiting only modest activity. Based on these results, we would not consider this combination for further investigation in this setting.

Iowa Agri-News, February 24, 2014, Vol. 14, no. 6

Crop and livestock summaries for the state of Iowa, produced by the Iowa Department of Agriculture. Previously Agri-News

Lottery Action, Vol. 20, No. 5, March 24-April 6, 2014

Retailer newsletter

Iowa Lottery Action, Vo. 20, No. 3 Feb. 24 - March 9, 2014

Iowa Lottery Retailer Newsletter

Iowa Lottery Action, Vol. 19, NO. 24, Dec. 16, 2013 - Jan. 5, 2014

Iowa Lottery Retailer Newsletter

Iowa Lottery Action, Vol. 19, No. 5, March 11-24, 2013

Iowa Lottery Retailer Newsletter